Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity. The company is holding significant cash and investments (~INR230 crores) and plans to use this for M&A opportunities. Management mentions a preference to keep reserves (~INR50 crores) to be ready for acquisitions rather than raising fresh capital. Expansion needs minimal capital (INR4-5 crores), supported by strong free cash flow (~INR40 crores annually). No concrete timeline for raising funds; focus is on utilizing existing treasury assets and internal accruals. M&A discussions are ongoing with hopes to

Any current/future capex/capital investment/strategic investment?

The company is well-positioned for expansion, currently utilizing around 50% of its capacity. Expected capex for capacity expansion is relatively low, approximately INR 4-5 crores. Free cash flow generation is strong, about INR 40 crores plus annually, leading to a significant cash balance available for investments. There is a clear focus on inorganic growth through M&A, with multiple consultants appointed in France, UK, and US to scout opportunities. M&A targets typically have a minimum topline of EUR 2 million, preferably EBITDA positive or turnaround candidates. The company aims to keep a c

Future growth expectations in sales/revenue/volumes?

The company targets a revenue growth of 15% to 20% for FY27 and onward. Coris is expected to contribute around INR50 crores in topline, growing slightly with EBITDA turning slightly positive in FY27, targeting 5%-10% EBITDA margin by FY28. The overall consolidated topline for FY27 is expected to be INR175-180 crores. The Indian domestic market is expected to grow around 15%, with international operations growing 20%-25%, leading to consolidated growth of 15%-20%. Competition from China affects a small product segment but is not expected to impact the core high-margin AMR panel business. Market

Future growth expectations in earnings/operating earnings/profits/EPS?

3B BlackBio DX Limited expects revenue growth of 15% to 20% annually, sustained over FY27 and FY28. EBITDA margins are projected to maintain or slightly improve, with consolidated EBITDA margins expected around 40%-45% excluding other income. Coris segment is anticipated to become slightly EBITDA positive in FY27, aiming for 5% to 10% EBITDA margin by FY28. Overall EBITDA growth is expected to mirror revenue growth (15%-20%), with Coris EBITDA flat or marginally positive in the near term. Depreciation for FY27 is estimated around INR 4.5 to 5 crores annually. The company plans strong

Current/ Expected Orderbook/ Pending Orders?

Coris contract initially was Euro 6 million for four years starting 2024. Out of Euro 6 million, approximately Euro 3.45 million has been executed (2.1 million + 1.35 million). Around Euro 2.4 million remains to be executed through FY28. The Coris HAT order is expected to remain broadly similar in the current year. Exact timing of order execution can be affected by external factors like Ebola outbreak in Congo, causing possible delays. For FY27, Coris is expected to be around INR 50 crores in revenue with EBITDA roughly flat or slightly positive. Market demand projected to grow at 8% to 10%, w

IN US

Sale is live|00:00:00left today

3B Blackbio DX LtdQ1 FY26Healthcare Services

3B Blackbio DX Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,170P/E: 20.5Market Cap: ₹1.2K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

N/A

Fundraise

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company targets a revenue growth of 15% to 20% for FY27 and onward.
→Coris is expected to contribute around INR50 crores in topline, growing slightly with EBITDA turning slightly positive in FY27, targeting 5%-10% EBITDA margin by FY28.
→The overall consolidated topline for FY27 is expected to be INR175-180 crores.
→The Indian domestic market is expected to grow around 15%, with international operations growing 20%-25%, leading to consolidated growth of 15%-20%.
→Competition from China affects a small product segment but is not expected to impact the core high-margin AMR panel business.
→Market growth is anticipated at 8%-10% over the next 2-3 years, with the company maintaining approximately 15% market share.
→Growth is supported by new product launches such as sample-to-answer systems expected around Q3-Q4, and ongoing US FDA approvals enhancing global presence.

Margin guidance

→3B BlackBio DX Limited expects revenue growth of 15% to 20% annually, sustained over FY27 and FY28.
→EBITDA margins are projected to maintain or slightly improve, with consolidated EBITDA margins expected around 40%-45% excluding other income.
→Coris segment is anticipated to become slightly EBITDA positive in FY27, aiming for 5% to 10% EBITDA margin by FY28.
→Overall EBITDA growth is expected to mirror revenue growth (15%-20%), with Coris EBITDA flat or marginally positive in the near term.
→Depreciation for FY27 is estimated around INR 4.5 to 5 crores annually.
→The company plans strong margin profiles supported by high-margin segments like AMR; competitive pressure from China is limited to a small product segment.
→EPS growth is implied aligned with revenue and EBITDA growth targets, though specific EPS figures were not disclosed.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned fundraising through debt or equity.
→The company is holding significant cash and investments (~INR230 crores) and plans to use this for M&A opportunities.
→Management mentions a preference to keep reserves (~INR50 crores) to be ready for acquisitions rather than raising fresh capital.
→Expansion needs minimal capital (INR4-5 crores), supported by strong free cash flow (~INR40 crores annually).
→No concrete timeline for raising funds; focus is on utilizing existing treasury assets and internal accruals.
→M&A discussions are ongoing with hopes to close deals within the year but depend on valuation and due diligence, not fundraising.
→Overall, emphasis is on organic growth and acquisitions funded by internal cash rather than fresh equity or debt.

Order book

→Coris contract initially was Euro 6 million for four years starting 2024.
→Out of Euro 6 million, approximately Euro 3.45 million has been executed (2.1 million + 1.35 million).
→Around Euro 2.4 million remains to be executed through FY28.
→The Coris HAT order is expected to remain broadly similar in the current year.
→Exact timing of order execution can be affected by external factors like Ebola outbreak in Congo, causing possible delays.
→For FY27, Coris is expected to be around INR 50 crores in revenue with EBITDA roughly flat or slightly positive.
→Market demand projected to grow at 8% to 10%, with 3B BlackBio maintaining around 15% market share.
→No major market glut expected from China or competitors in India or export markets due to regulatory barriers.

Capex plans

Yes

→The company is well-positioned for expansion, currently utilizing around 50% of its capacity.
→Expected capex for capacity expansion is relatively low, approximately INR 4-5 crores.
→Free cash flow generation is strong, about INR 40 crores plus annually, leading to a significant cash balance available for investments.
→There is a clear focus on inorganic growth through M&A, with multiple consultants appointed in France, UK, and US to scout opportunities.
→M&A targets typically have a minimum topline of EUR 2 million, preferably EBITDA positive or turnaround candidates.
→The company aims to keep a cash reserve of INR 50 crores specifically for M&A deals.
→Slight uncertainties exist on timing; M&A closures are expected during the year but exact Q1/Q2 timing is not guaranteed.
→Treasury investments are diversified into equity mutual funds (5-7%), fixed deposits (30-35%), treasury bonds (30-35%), and AAA-rated corporate bonds, maintaining liquidity for acquisitions.

How does 3B Blackbio DX Ltd rank vs peers in Healthcare Services?

Pro feature

13B Blackbio DX Ltd

Rev 3

See full Healthcare Services sector rankings

Want more stocks like 3B Blackbio DX Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio